Constitutive activation of m TOR signaling pathway in post-transplant lymphoproliferative disorders
El-Salem M, Raghunath PN, Marzec M, et al. Constitutive activation of m TOR signaling pathway in post-transplant lymphoproliferative disorders. Lab Invest 2007 87 : 29.
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004 22 : 2336.
World Health Organization classification of neoplastic diseases of hematopoietic and lymphoid tissues; Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of hematopoietic and lymphoid tissues; report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999 17 : 3835.
Resolution of renal allograft-associated post-transplant lymphoproliferative disordr with the introduction of sirolimus
Zaltzman J, Prasad R, Chun K, Jothy S. Resolution of renal allograft-associated post-transplant lymphoproliferative disordr with the introduction of sirolimus. Nephrol Dial Transplant 2005 20 : 1748.
Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma
Jimenez-Rivera C, Avitzur Y, Fecteau A, et al. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 2004 8 : 243.